Insmed (NASDAQ:INSM) CEO William Lewis Sells 10,699 Shares

Key Points

• Insmed CEO William Lewis sold 10,699 shares on April 6 at an average price of $163.22 under a pre-arranged Rule 10b5-1 plan, cutting his stake by about 3.43% to 301,185 shares — one of several recent insider sales.
• The company will discontinue development of brensocatib for hidradenitis suppurativa after the Phase 2b CEDAR study failed to meet primary and secondary endpoints, with placebo outperforming treatment.
• Despite the clinical setback, analysts remain largely bullish: Insmed has an average "Buy" consensus and a $212.67 mean price target, with some firms (e.g., Goldman, Barclays) raising targets into the $230–$258 range.

Insmed, Inc. (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 10,699 shares of the business's stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $163.22, for a total value of $1,746,290.78. Following the sale, the chief executive officer owned 301,185 shares of the company's stock, valued at approximately $49,159,415.70. This represents a 3.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

William Lewis also recently made the following trade(s):

• On Thursday, March 19th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $143.52, for a total value of $1,535,520.48.
• On Thursday, March 5th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $146.03, for a total value of $1,562,374.97.
• On Thursday, February 19th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $150.97, for a total value of $1,615,228.03.
• On Monday, February 9th, William Lewis sold 13,396 shares of Insmed stock. The stock was sold at an average price of $147.79, for a total value of $1,979,794.84.
• On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The stock was sold at an average price of $156.34, for a total value of $470,427.06.
• On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $158.93, for a total value of $1,700,392.07.
• On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The stock was sold at an average price of $169.00, for a total value of $3,247,335.00.
• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total value of $561,349.91.

Insmed Stock Performance

Shares of NASDAQ:INSM traded down $2.85 during trading on Wednesday, reaching $160.18. 3,355,973 shares of the stock were exchanged, compared to its average volume of 2,538,183. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $212.75. The firm has a market cap of $34.57 billion, a PE ratio of -24.99 and a beta of 1.10. The stock has a 50-day moving average price of $150.39 and a 200-day moving average price of $167.08. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm had revenue of $263.84 million for the quarter, compared to the consensus estimate of $263.97 million. During the same quarter in the prior year, the firm earned ($1.32) EPS. The company's revenue was up 152.6% on a year-over-year basis. Research analysts expect that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in INSM. CW Advisors LLC acquired a new position in Insmed during the second quarter valued at approximately $576,000. EverSource Wealth Advisors LLC raised its position in Insmed by 65.6% during the second quarter. EverSource Wealth Advisors LLC now owns 664 shares of the biopharmaceutical company's stock valued at $67,000 after purchasing an additional 263 shares in the last quarter. First Trust Advisors LP raised its position in Insmed by 80.8% during the second quarter. First Trust Advisors LP now owns 47,392 shares of the biopharmaceutical company's stock valued at $4,770,000 after purchasing an additional 21,176 shares in the last quarter. Baird Financial Group Inc. acquired a new position in Insmed during the second quarter valued at approximately $2,589,000. Finally, Amundi raised its position in Insmed by 21,194.4% during the second quarter. Amundi now owns 11,499 shares of the biopharmaceutical company's stock valued at $1,130,000 after purchasing an additional 11,445 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on INSM shares. Barclays boosted their price target on Insmed from $231.00 to $237.00 and gave the company an "overweight" rating in a research note on Wednesday, April 1st. TD Cowen set a $241.00 price target on Insmed in a research note on Thursday, December 18th. Jefferies Financial Group started coverage on Insmed in a research note on Monday, March 16th. They issued a "buy" rating and a $228.00 price target for the company. UBS Group cut their price target on Insmed from $223.00 to $215.00 and set a "buy" rating for the company in a research note on Tuesday, January 6th. Finally, The Goldman Sachs Group boosted their price target on Insmed from $225.00 to $258.00 and gave the company a "buy" rating in a research note on Monday, December 15th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $212.67.

More Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Company says safety profile for brensocatib in the Phase 2b CEDAR study was consistent with prior trials and no new safety signals were identified, which limits downside from unexpected safety issues and preserves value for remaining programs. Insmed Provides Clinical Update on Phase 2b CEDAR Study
• Neutral Sentiment: Market commentators noted the brensocatib miss was largely anticipated by some investors/analysts, which may have tempered the reaction versus a surprise blow-up. Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs ‘expected’ study failure
• Neutral Sentiment: Trading in INSM was briefly halted when the company announced the clinical update, a common market response to material news but not a directional signal by itself. Insmed discontinues development of skin condition drug after mid-stage study miss
• Neutral Sentiment: Billionaire Stan Druckenmiller trimmed his position in Insmed (Duquesne Capital history noted), a disclosure that may reduce some activist/large-holder support but does not reflect current company fundamentals on its own. Insmed Incorporated (INSM): Billionaire Stan Druckenmiller Trims Stake
• Negative Sentiment: Insmed will discontinue development of brensocatib for hidradenitis suppurativa (HS) after the Phase 2b CEDAR study failed to meet primary and secondary endpoints (both 10 mg and 40 mg arms). Management said it will stop the HS program — this removes a potential indication and reduces the drug’s near-term upside. Insmed discontinues development of skin condition drug after mid-stage study miss
• Negative Sentiment: Multiple outlets report the Phase 2b placebo outperformed treatment, prompting program freeze/termination; investors are pricing loss of HS indication and the R&D cost sunk into this program. Insmed’s Brinsupri flops hidradenitis suppurativa study

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.